OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment
Source: SeekingAlpha
2025-03-31 10:01:55 ET
More on OKYO Pharma
- OKYO Pharma receives $1.4 million in non-dilutive funding, stock up
- Seeking Alpha’s Quant Rating on OKYO Pharma
- Historical earnings data for OKYO Pharma
- Financial information for OKYO Pharma
Read the full article on Seeking Alpha
For further details see:
OKYO Pharma reports long-term benefits of its neuropathic corneal pain treatment
OKYO Pharma Limited
NASDAQ: OKYO
OKYO Trading
-2.34% G/L:
$1.6798 Last:
29,165 Volume:
$1.68 Open:
OKYO Latest News
February 23, 2026 11:00:00 am
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress
February 12, 2026 10:20:03 pm
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
OKYO Stock Data
$70,725,600
24,520,464
35.96%
8
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
